Clinical trial · Interventional
Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus
NCT02168426CI-TRIAL-00018999completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the efficacy of Seprafilm and guardix in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm and guardix occurring within 30 days postoperatively.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patient Under Going Colorectal and Stomach Cancer Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Guardix | Procedure | — | UNRESOLVED |
| Seprafilm | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Guardix
- description
- 6g per body
- interventionNames
- Procedure: Guardix
- Procedure: Seprafilm
- type
- ACTIVE_COMPARATOR
- label
- Seprafilm
- description
- 1 sheet per body
- interventionNames
- Procedure: Guardix
- Procedure: Seprafilm
Primary outcomes (1)
- measure
- ileus rate
- timeFrame
- within 60 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of GI cancer * Operable Exclusion Criteria: * Withdrew consent * Pregnant * Ascites * Distant metastasis * Liver dysfunction (serum total bilirubin \>2.0 mg/dL) * Renal failure (serum creatinine \>1.5 mg/dL) * A past history of small bowel obstruction.
References
Publications (0)
Data not yet available
No reference posted for this study.